RE: Comparison to gilts21 May 2025 11:20
Good points by both Couerdelion and joedjoed.
The markets have punished the valuations of the life insurance sector since the Kamakwasi budget and, just as valuations were recovering, gave them another kicking after the collapse of Silicon Valley Bank.
The markets have been treating the life insurers as if they are exposed to bond prices when, in reality, they are only exposed to bond default.
Life insurers buy bonds to match underlying liabilities. The investment case for those bond investments is that they provide a known margin against know liabilities and are held to maturity. The investments are only sold if it provides an upside to the life insurer - i.e. they can make a larger margin by trading the underlying investment. There's a good segment on this stuff in the Q&A that L&G did in their 4 Dec capital markets event (https://group.legalandgeneral.com/en/reporting-hub/Capital%20Markets%20Events).
The IFRS17 accounting changes also haven't helped as - when combined with the requirement to mark to market - it makes the companies look like they're losing money.
The net result is that the life insurers have been trading on a 4-5% risk premium against 2%(ish) historically.
I do sense a bit of a rerate going on - partly because of investment rotation from the US and partly because the CEOs/CFOs have been better at communicating the underlying investment cases.
I agree with Couerdelion that a comparison to bond yields constrains the upper share price bound, but even a rerate from a 9% yield to a 7% yield would get the price to around £8. joedjoed's insight on what to rate against is insightful and, if we assume a comparison against 4% bond yield, then 7% still provides a 3% risk premium.
So, personally, I wouldn't be surprised if we could get to £8. But that's probably the upper bound of what can be expected on current performance.
Other viewpoints appreciated :)